Mi­rati steps on the gas with KRAS in­hibitor, look­ing to claim sec­ond ap­proval be­hind Am­gen's Lumakras

Am­gen beat Mi­rati to the fin­ish line with the first-ever ap­proved KRAS in­hibitor back in May. But Mi­rati’s pick­ing up the pace and says it could be look­ing to carve out a space on the mar­ket by the end of the year with what it thinks is the bet­ter of the two da­ta sets as monother­a­py.

The FDA has grant­ed break­through des­ig­na­tion to Mi­rati’s ada­gra­sib in non-small cell lung can­cer pa­tients with the KRAS-G12C mu­ta­tion fol­low­ing pri­or ther­a­py, the com­pa­ny said on Thurs­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.